Today's headlines include stories examining how the approaching implementation of some health law provisions is highlighting key policy questions.
[More]
InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.
[More]
Omeros Corporation today reported analyses of Phase 2 and Phase 3 clinical data showing the favorable impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement.
[More]
Sony Electronics, a leader in providing innovative imaging solutions for microsurgery, announces the first east and west coast installations of its end-to-end 3D imaging solution for ophthalmic surgery.
[More]
Bausch + Lomb, the global eye health company, today announced that the U.S. Food and Drug Administration has approved the company's New Drug Application for PROLENSA (bromfenac ophthalmic solution) 0.07 percent prescription eye drop, an innovative once-daily nonsteroidal anti-inflammatory drug for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
[More]
LENSAR Inc., developer of the next generation LENSAR Laser System™ for refractive cataract surgery, announced today that the company's laser system has received 510(k) clearance from the United States Food and Drug Administration for the execution of arcuate incisions during cataract surgery.
[More]
Recent study findings indicate that eyes with multifocal intraocular lenses implanted during cataract surgery may develop reduced visual sensitivity.
[More]
Avedro, Inc. announced today the completion of a $43 million Series D financing led by Abingworth along with a significant investment by Third Point.
[More]
A professor at London's Kingston University has made a discovery about the shape of the eye that could boost the effectiveness of man-made lenses used in cataract operations.
[More]
Oraya Therapeutics, Inc. today announced that one of the patients who successfully was treated for wet age-related macular degeneration (AMD) with Oraya Therapy during the INTREPID clinical trial has released data showing he has experienced significant, sustained vision improvement more than two years after treatment in his right eye, without any subsequent anti-vascular endothelial growth factor (anti-VEGF) injections or other treatment.
[More]
Clearview Eye & Laser Medical Center announces the arrival of the world's most sophisticated laser cataract surgery system in Southern CA.
[More]
The causes and prevalence of blindness in children vary markedly by geography, presumably as a proxy for socioeconomic factors influencing prevention and treatment schemes, conclude the authors of a literature review.
[More]
A 20-page large-print booklet and a series of videos to help people adapt to life with low vision are available from the National Eye Institute (NEI), a part of the National Institutes of Health. The materials were released during Low Vision Awareness Month, February 2013.
[More]
A cure for congenital sight impairment caused by lens damage is closer following research by scientists at Monash University.
[More]
This week, a study published in the journal JAMA Internal Medicine, explored the connection between regular aspirin use and the potential risks for developing the blinding eye disease, macular degeneration. As a result, there is increased confusion and anxiety in the general public about whether aspirin can harm your vision and what to do if you need the heart-protective therapy.
[More]
AMD is the leading cause of vision loss in anyone over 50 and globally in 2010 it was estimated to cost $340 billion to treat AMD. The costs are set to spiral over the next 20 years and really over burden the healthcare system unless people start to take preventative action.
[More]
A new series of studies in mouse models by Mayo Clinic researchers uncovered that the aging process is characterized by high rates of whole-chromosome losses and gains in various organs, including heart, muscle, kidney and eye, and demonstrate that reducing these rates slows age-related tissue deterioration and promotes a healthier life span. The findings appear in today's online issue of Nature Cell Biology.
[More]
The prevalence of nonrefractive visual impairment (not due to need for glasses) in the U.S. has increased significantly in recent years, which may be partly related to a higher prevalence of diabetes, an associated risk factor, according to a study in the December 12 issue of JAMA.
[More]
LENSAR Inc., developer of the next generation LENSAR Laser System™ for refractive cataract surgery, announced today that the company's laser system has received 510(k) clearance from the United States Food and Drug Administration (FDA) for executing corneal incisions during cataract surgery.
[More]
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for EYLEA (aflibercept) Injection for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO).
[More]